Jefferies Group’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-7,500
Closed -$1.9M 1804
2021
Q4
$1.9M Sell
7,500
-3,000
-29% -$877K 0.01% 798
2021
Q3
$4.04M Buy
10,500
+3,000
+40% +$1.11M 0.03% 500
2021
Q2
$1.76M Hold
7,500
0.01% 790
2021
Q1
$982K Sell
7,500
-420,900
-98% -$61M 0.01% 919
2020
Q4
$44.8M Buy
428,400
+385,200
+892% +$39M 0.35% 37
2020
Q3
$3.06M Buy
43,200
+17,200
+66% +$1.2M 0.03% 421
2020
Q2
$1.67K Buy
+26,000
New +$1.42M 0.02% 621

Other funds holding MRNA

Jefferies Group's MRNA Position: Q3 2022 in Review

Jefferies Group sold out of Moderna (MRNA) in Q3 2022, closing a stake of 3,752 shares — an estimated $536K sold.

Jefferies Group first reported a position in MRNA in Q2 2019 and held it in 10 quarters. The position peaked at $35M in Q3 2021. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

  • Jefferies Group reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
  • Jefferies Group sold 3,752 Moderna shares in Q3 2022, an estimated $536K.
  • Jefferies Group first reported a position in Moderna in Q2 2019 and held it in 10 quarters.
  • Jefferies Group's Moderna position peaked at $35M in Q3 2021.
  • 915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.